PMID: 35441470 Lincoff AM, Brown-Frandsen K, Colhoun HM,
Semaglutide or Tirzepatide, including micro-dose programs, cannot be prescribed and should not be purchased by individuals with a BMI under 25, an eating disorder, diabetes, gallbladder disease, history of drug or alcohol abuse, recent bariatric surgery, pancreatitis, medullary thyroid cancer or a family history of it, diabetic retinopathy, multiple endocrine neoplasia type 2, or those who are pregnant, breastfeeding, or planning to become pregnant
Many patients have reported that after initial weeks of therapy, the incidence of nausea decreases significantly or disappears altogether
For residents seeking semaglutide without insurance, compounded alternatives from FDA-registered 503B facilities and telehealth providers have created access where the retail system failed
Maybe you are that person
Doseresponse modeling, meta-analysis, and Bayesian hierarchical models were implemented using validated statistical packages